Redeye Orphan Drugs
VirtualAbliva will participate at Redeye's seminar on ‘Drug development in orphan indications.’ CEO Ellen Donnelly will be presenting the company at 10:55 a.m. CEST. Follow link below for further details and live webcast.
Delivering mitochondrial health
Abliva will participate at Redeye's seminar on ‘Drug development in orphan indications.’ CEO Ellen Donnelly will be presenting the company at 10:55 a.m. CEST. Follow link below for further details and live webcast.
CEO Ellen Donnelly will present the company at 1:20 p.m. CEST.
Abliva would like to invite interested shareholders and investors to a fun and informal “Fireside Chat” with the company's CEO, Ellen Donnelly, and members of the Abliva team, in Stockholm (28 September) and Lund (29 September). After a long stretch of stringent travel restrictions and two-dimensional zoom presentations, we would like to invite Abliva shareholders […]
Abliva will attend Aktiespararna's Kvinnokvällen Malmö, on 19 October 2021.. CEO Ellen Donnelly will be presenting the company at 7:30 p.m. CEST.
Abliva will attend the BioStock Life Science Summit 2021. CEO Ellen Donnelly will be presenting the company on 20 October at 2:00 p.m. CEST.
Abliva invites to a conference call and an online presentation on June 1, 2022, at 14:00 CEST. Abliva's CEO Ellen Donnelly, CMO Magnus Hansson and CFO Catharina Johansson will inform about the financing and implementation of KL1333 Phase 2/3 study and answer questions. The presentation will be held in English. After the presentation, there will […]
In light of our recent announcement and the continued developments in the company, we would like to invite shareholders and interested investors to an informal gathering to hear more about the path forward directly from Ellen Donnelly (CEO) and the Abliva team. We hope you will join us in Lund during the Midsummer week to […]